pcn poster

Posters

Incidence and Characteristics of Akathisia With Adjunctive Cariprazine Treatment in Patients With Major Depressive Disorder

Incidence of akathisia was higher for cariprazine than placebo, with lower incidence observed for patients treated with cariprazine 1.5mg/d+ADT versus 3mg/d+ADT, suggesting dose related e...

Majid Kerolous , PharmD, MPH;

10/26/2023

Impact of Lemborexant on Daytime Sleepiness/Alertness in Subjects With Insomnia Disorder and Baseline Sleepiness

Some sleep medications may cause morning sleepiness due to sedative side effects. This post-hoc analysis of Study 304 showed that lemborexant (LEM), a competitive dual orexin receptor ant...

Margaret Moline , PhD;

10/26/2023

Impact of Treatment With TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), at Different Stages of Schizophrenia: a Post Hoc Analysis

TV-46000 is an FDA-approved long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone that has been shown to reduce time to impending relapse in patients with schizophreni...

Kelli R. Franzenburg , PhD;

10/26/2023

Implementation of Exercise Reminders to Improve Symptoms of Clinical Depression

This poster is part of the requirement in fulfillment of a Doctor of Nursing Practice (DNP) degree at Rutgers University, School of Nursing. The purpose of the project is to improve the s...

Femi R. Omidire , APN, PHMNP-BC;

10/26/2023

Improvements in Cognitive and Physical Functioning Outcomes in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-Label, Long-Term Study

AXS-05 exhibited rapid and sustained improvements in cognitive and physical functioning in individuals with MDD who previously tried one or more prior antidepressants. This study also sho...

Shawn Alter , PhD;

10/26/2023

Improvements in Daytime Functioning With Lemborexant Treatment

Daytime impairment can be assessed by items 4-7 of the 7-item Insomnia Severity Index. Here we report the impact of lemborexant (LEM) versus placebo on shifts in daytime-function-specific...

Margaret Moline , PhD;

10/26/2023

Huffing and Puffing with Olanzapine: Olanzapine-Induced Dyspnea

This case report demonstrates a relationship between Olanzapine and hyperventilation. Increased minute ventilation on the ventilator while on olanzapine therapy, lack of other causes of i...

Aung Sitt Naing , MD;

10/26/2023

Impact of Adjunctive Cariprazine on Quality of Life in Major Depressive Disorder: A Post Hoc Analysis

Patients with major depressive disorder often have reduced quality of life. A previous phase 3 trial showed cariprazine adjunctive to antidepressant therapy reduces depressive symptoms in...

Nadia Nabulsi , MPH, PhD;

10/26/2023

Impact of AXS-05 (Dextromethorphan-Bupropion) on Patient-Reported Insomnia Symptoms: Results from the GEMINI Trial

In GEMINI, AXS-05, an oral NMDA receptor antagonist approved for MDD, showed significantly higher response rates (defined as 50% reduction in QIDS insomnia score) starting at Week 3 throu...

William Olsufka , PharmD;

10/26/2023

Impact of Fremanezumab Treatment on Disability Outcomes in Patients With Migraine and Major Depressive Disorder: Results of the UNITE Study

Depression is a prevalent comorbidity associated with migraine, and the bidirectional relationship between the two disorders can negatively impact quality of life (QoL). During the 12-wee...

Peter McAllister , MD;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products